FIELD trial

Fenofibrate Intervention and Event Lowering in Diabetes: prevention of coronary heart disease with fenofibrate in people with diabetes.

The FIELD trial Fenofibrate Intervention and Event Lowering in Diabetes aims to determine whether treatment with fenofibrate, a potent modifier of blood lipid levels, will reduce the risk of fatal coronary heart disease in people with type 2 diabetes.

Official Title

Conditions

Study Type

Study Design

Further Details

FIELD will determine whether strokes and deaths can be prevented in people with diabetes treated with fenofibrate. FIELD is internationally managed by the CTC. The core team supports a management structure headed by the study chairman, Associate Professor Anthony Keech, and the international Management Committee, which has representatives from the three participating countriesAustralia, New Zealand and Finland-and the sponsor, the French pharmaceutical company Laboratoires Fournier. FIELD randomly assigned the last of its 9795 participants in November 2000, and one of the challenges throughout the study period will be to follow up all the participants and keep the number of patients dropping out to a minimum. In this follow-up stage of the study, which will run for 5 to 7 years, participants are visiting for follow-up at six-monthly intervals.

Study Start

Nov 2000

Eligibility & Criteria

type 2 diabetes mellitus with onset after the age of 35 years men and women aged 5075 years of age average total cholesterol 3.06.5 mmol/L triglycerides/high-density cholesterol ratio of 4.0 or higher, or triglycerides over 1.0 mmol/L

Total Enrolment

9795

Contact Details

FIELD project manager: Elizabeth KeirnanFIELD chairman: Anthony Keech CTC